Curated Wealth Partners 13F: Cuts Amgen (AMGN) Stake by $183M

Curated Wealth Partners pulled back sharply on its investment in Amgen Inc. AMGN, according to a Form 13F filed with the SEC on October 15, 2026. Because 13F filings look backward, the report captures portfolio choices made during the period but might not reflect the fund's exact current holdings.

Inside Curated Wealth Partners's Amgen Trade

During the period, Curated Wealth Partners trimmed its holdings by 99.62%. The fund dropped 433,767 shares, leaving it with just 1,618 shares at the end of the quarter. The remaining stake was valued at approximately $682,007 based on the filing data, down significantly from its previous holding of 435,385 shares.

Other Institutional Activity in Amgen

Other large institutional investors made adjustments to their Amgen positions around the same reporting window. Blackrock Inc. grew its holdings by 2,260,856 shares, ending with 49,362,016 shares worth about $21,348,577,817 after a 4.8% increase. Vanguard Capital Management LLC boosted its stake by 234,604 shares, bringing its total to 35,250,101 shares valued at about $15,245,315,837 following a 0.7% lift. State Street Corporation held steady, adding 12,219 shares to reach 30,560,537 shares worth roughly $13,217,126,348. Capital World Investors trimmed its position by 213,811 shares, or 0.7%, leaving it with 29,075,329 shares valued at about $12,574,788,755. Finally, Invesco Ltd. lifted its stake by 435,254 shares, or 2.7%, ending with 16,320,446 shares worth about $7,058,429,531.

Amgen Inc. Stock Up 1.4%

Amgen shares recently traded around $432.06 as of October 16, 2026. The stock is trading about 4.2% above its 50-day moving average of $414.46 and roughly 17.3% above its 200-day moving average of $368.38. The shares sit about 3.3% below their 52-week high of $447.03 and roughly 50.0% above their 52-week low of $288.00.

Recent Earnings

Amgen reported trailing-twelve-month revenue of $38,094,999,552 with a year-over-year revenue growth rate of 9.5%. The company posted trailing-twelve-month earnings per share of $16.10, alongside a net profit margin of 23.0% and a return on equity of 91.5%. The company's next earnings report is scheduled for November 3, 2026.

Dividend

Amgen pays an annualized dividend yielding 2.32%, supported by a dividend payout ratio of 60.9%.

Insider Buying and Selling at Amgen Inc.

Company insiders executed several transactions prior to the filing. On August 6, 2026, officer Nancy A Grygiel sold 2,970 shares at an average price of $402.16, totaling $1,194,415. On the same day, officer Derek Miller sold 3,890 shares at $402.54 per share, for a total value of $1,565,898. Later, on August 13, 2026, officer Rachna Khosla sold 3,252 shares valued at $1,346,499.

Analysts Set New Price Targets

Wall Street firms updated their outlooks on Amgen through October 2026. On October 8, 2026, RBC Capital maintained its Outperform rating and raised its price target to $430.00 from $400.00. On October 9, 2026, UBS maintained its Buy rating and boosted its target to $470.00 from $430.00. On October 12, 2026, BMO Capital maintained a Market Perform rating while lowering its target from $450.00 to $415.00. Wells Fargo maintained an Equal-Weight rating on October 12, 2026, adjusting its target down to $430.00 from $435.00. On October 13, 2026, Guggenheim maintained a Neutral rating and cut its target to $378.00 from $388.00. Across the broader analyst community, the stock holds a consensus Hold recommendation with a mean price target of $394.98 based on 29 analyst opinions.

About Amgen

Headquartered in Thousand Oaks, California, Amgen discovers, develops, manufactures, and delivers human therapeutics across multiple global healthcare markets. The large-cap biopharmaceutical company operates within the drug manufacturing sector, developing treatments for serious illnesses.

Bottom Line

Investors will look to Amgen's upcoming earnings release on November 3, 2026, for further financial updates. Institutional reports like this 13F filing provide a look back at portfolio adjustments, while ongoing market activity will dictate how the stock performs next. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.